Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Completed Phase 2 Trials for Cyclosporine (DB00091)

Back to Recurrent Adult Diffuse Small Cleaved Cell Lymphoma

Indication	Status	Phase
DBCOND0028499 (Recurrent Adult Diffuse Small Cleaved Cell Lymphoma)	Completed	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT01177371	High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma	Treatment	Busulfan (DB01008) Cyclophosphamide (DB00531) Cyclosporine (DB00091) Methotrexate (DB00563) Methylprednisolone (DB00959) Methylprednisolone hemisuccinate (DB14644)
NCT00118352	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Treatment	Alemtuzumab (DB00087) Cyclosporine (DB00091) Fludarabine (DB01073) Mycophenolate mofetil (DB00688)
NCT01093586	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Treatment	Antilymphocyte immunoglobulin (horse) (DB09312) Antithymocyte immunoglobulin (rabbit) (DB00098) Busulfan (DB01008) Cyclophosphamide (DB00531) Cyclosporine (DB00091) Methylprednisolone (DB00959) Methylprednisolone hemisuccinate (DB14644) Mycophenolate mofetil (DB00688)
NCT00040846	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies	Treatment	Alemtuzumab (DB00087) Cyclosporine (DB00091) Fludarabine (DB01073) Mycophenolate mofetil (DB00688)
NCT00119392	Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Treatment	Cyclosporine (DB00091) Fludarabine (DB01073) Mycophenolate mofetil (DB00688) Rituximab (DB00073)
NCT01427881	Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	Treatment	Busulfan (DB01008) Cyclophosphamide (DB00531) Cyclosporine (DB00091) Fludarabine (DB01073)
NCT01789255	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies	Supportive Care	Cyclosporine (DB00091) Methotrexate (DB00563) Tacrolimus (DB00864) Vorinostat (DB02546)